Pelthos Therapeutics vs Scilex
PTHS and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTHS and SCLX compare
Pelthos Therapeutics is the larger company, worth 2.5 times as much as Scilex ($26.2M against $10.6M).
Pelthos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −200% compared with −1470% at Scilex.
Pelthos Therapeutics scores higher on the StockData Score (2 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTHS | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $26.2M | $10.6M |
| Share price | $6.84 | $1.25 |
| Change, 1 year | −79.6% | −93.0% |
| Change, 5 years | – | −99.6% |
| Beta (5Y) | 0.97 | 2.18 |
| Employees | 92 | 34 |
| StockData Score | ||
| Total score | 2 (better) | 1 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.6× | 0.3× (better) |
| Growth | ||
| Revenue growth (TTM) | – | −28.5% |
| Revenue growth, 5Y average | – | 5.1% |
| Profitability | ||
| Gross margin | 78.6% | 161% (better) |
| Operating margin | −133% (better) | −1136% |
| Net margin | −200% (better) | −1470% |
| Financial health | ||
| Interest coverage | −7.8× (better) | −22.2× |
| Current ratio | 1.98 (better) | 0.07 |
| Altman Z-score | −1.84 (better) | −12.75 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 35.6% | 9.8% |
| Insider net buying, 12 months | $794K (better) | −$12.8M |
Go deeper
- PTHS stock overview
- PTHS income statement
- PTHS valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.